Somewhat Favorable News Coverage Very Unlikely to Impact Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Price

News headlines about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 25 out of 100, indicating that recent press coverage is very unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Accern’s scoring:

Teva Pharmaceutical Industries Limited (TEVA) traded down 0.34% during mid-day trading on Friday, hitting $32.34. 4,046,745 shares of the company were exchanged. The company has a market cap of $32.86 billion, a price-to-earnings ratio of 414.62 and a beta of 0.47. The stock’s 50 day moving average is $31.96 and its 200-day moving average is $32.34. Teva Pharmaceutical Industries Limited has a 12-month low of $27.60 and a 12-month high of $55.79.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, May 11th. The company reported $1.06 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The company had revenue of $5.63 billion for the quarter, compared to the consensus estimate of $5.69 billion. During the same quarter in the previous year, the company earned $1.20 EPS. The firm’s revenue for the quarter was up 17.0% compared to the same quarter last year. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current year.

Several research analysts have recently weighed in on TEVA shares. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Deutsche Bank AG decreased their target price on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, May 12th. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $37.48 target price for the company in a research note on Tuesday, April 11th. Cowen and Company restated an “outperform” rating and issued a $50.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, April 4th. Finally, Citigroup Inc. decreased their target price on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, April 25th. Fifteen investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Teva Pharmaceutical Industries Limited currently has an average rating of “Buy” and a consensus price target of $42.88.

ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.chaffeybreeze.com/2017/07/29/teva-pharmaceutical-industries-limited-nyseteva-given-daily-media-sentiment-score-of-0-17-updated-updated-updated.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply